Royalty Pharma (RPRX) Interest Expenses (2019 - 2026)

Royalty Pharma has disclosed Interest Expenses across 8 years of filings, most recently posting $93.7 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $93.7 million, up 43.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $336.1 million (up 36.34% YoY), and the FY2025 annual result was $307.7 million, up 36.43% from the prior year.
• Interest Expenses came in at $93.7 million for Q1 2026 at Royalty Pharma, roughly flat from $94.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $94.2 million in Q4 2025 to a low of $44.2 million in Q1 2024.
• The 5-year median for Interest Expenses is $47.3 million (2023), against an average of $58.9 million.
• Across the five-year window, Interest Expenses retreated 5.79% in 2024 and jumped 47.54% in 2025, its largest moves.
• Royalty Pharma's Interest Expenses stood at $47.0 million in 2022, then grew by 0.64% to $47.3 million in 2023, then soared by 39.16% to $65.8 million in 2024, then surged by 43.2% to $94.2 million in 2025, then slipped by 0.48% to $93.7 million in 2026.
• The last three Interest Expenses figures came in at $93.7 million (Q1 2026), $94.2 million (Q4 2025), and $79.6 million (Q3 2025), per Business Quant data.